More about

Dapagliflozin

News
August 25, 2020
2 min read
Save

Dapagliflozin improves endothelial function, microvascular reactivity in type 2 diabetes

Dapagliflozin improves endothelial function, microvascular reactivity in type 2 diabetes

Patients with diabetes experienced significant improvement in endothelial function and microvascular reactivity while taking daily dapagliflozin, according to research presented at the virtual Heart in Diabetes Conference.

News
August 24, 2020
3 min read
Save

A ‘chicken or egg’ problem: Targeting timing of CV complications in type 2 diabetes

A ‘chicken or egg’ problem: Targeting timing of CV complications in type 2 diabetes

Lifestyle or medical therapy in prediabetes to reduce later cardiovascular events in type 2 diabetes may seem wise, yet little evidence demonstrates such strategies make a difference, according to a speaker.

News
August 22, 2020
3 min read
Save

DARE-19: Dapagliflozin could target key mechanisms activated in COVID-19

DARE-19: Dapagliflozin could target key mechanisms activated in COVID-19

SGLT2 inhibitors could potentially target key mechanisms activated in COVID-19, increasing lipolysis, reducing glycolysis, inflammation and oxidative stress, and improving endothelial function to reduce organ damage, according to a speaker.

News
August 22, 2020
4 min read
Save

SGLT2 inhibitors ‘changed the landscape’ in HF irrespective of diabetes status

SGLT2 inhibitors ‘changed the landscape’ in HF irrespective of diabetes status

SGLT2 inhibitors reduce HF in patients with atherosclerotic CVD or risk factors regardless of diabetes status, but more data are needed particularly in HF with preserved ejection fraction, according to a speaker.

News
July 28, 2020
1 min read
Save

Dapagliflozin slows renal disease, reduces death risk regardless of diabetes status

Dapagliflozin slows renal disease, reduces death risk regardless of diabetes status

The SGLT2 inhibitor dapagliflozin was linked to significant reductions in worsening renal function and renal or cardiovascular death in adults with chronic kidney disease irrespective of type 2 diabetes, according to a press release.

News
July 22, 2020
2 min read
Save

Dapagliflozin remains safe, effective for HF irrespective of diuretic use

Dapagliflozin remains safe, effective for HF irrespective of diuretic use

Dapagliflozin for worsening HF was both safe and efficacious regardless of diuretic use or dose, according to findings from the DAPA-HF trial published in Circulation.

News
July 06, 2020
2 min read
Save

Top data from ADA: SGLT2s, prescription fish oil, bempedoic acid address comorbidities

Top data from ADA: SGLT2s, prescription fish oil, bempedoic acid address comorbidities

Healio and Endocrine Today have compiled a list of the most read news from the virtual American Diabetes Association Scientific Sessions.

News
June 24, 2020
1 min read
Save

Top in endocrinology: Dapagliflozin, new integrated continuous glucose monitor

Top in endocrinology: Dapagliflozin, new integrated continuous glucose monitor

New data from the DAPA-HF trial showed that dapagliflozin was associated with a 32% lower risk for new-onset type 2 diabetes among patients with heart failure. It was the top story in endocrinology last week.

News
June 16, 2020
2 min read
Save

DAPA-HF: Dapagliflozin reduces new-onset diabetes among adults with heart failure

DAPA-HF: Dapagliflozin reduces new-onset diabetes among adults with heart failure

Adults with heart failure assigned the SGLT2 inhibitor dapagliflozin had a 32% lower risk for new-onset type 2 diabetes over 18 months of follow-up vs. placebo, according to a planned analysis of DAPA-HF trial data.

News
June 02, 2020
2 min read
Save

Top news of May: BP control via medication reduction, dapagliflozin approval and more

Top news of May: BP control via medication reduction, dapagliflozin approval and more

Healio and Cardiology Today have compiled a list of the top cardiology news from the month of May.

View more